NHS to offer 'groundbreaking' sickle cell gene therapy
- A new gene therapy called Casgevy, costing £1.65 million, has been approved for use on the NHS for patients with severe sickle cell disease, offering hope for a potential cure.
- About 1,700 patients may be eligible for the treatment, with an estimated 50 patients expected to receive it each year.
- In clinical trials, all patients who received Casgevy avoided hospital admissions for a year, and nearly 98% remained out of the hospital after 3.5 years.
- NHS Chief Executive Amanda Pritchard stated that the treatment could be 'absolutely transformative' for patients suffering from sickle cell disease.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left3Leaning Right4Center3Last UpdatedBias Distribution40% Right
Bias Distribution
- 40% of the sources lean Right
40% Right
L 30%
C 30%
R 40%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
